French biopharmaceutical company Transgene has randomised its first patient in the multiple-dose cohort of its Phase I/Ib trial of TG1050 to treat chronic hepatitis B virus (HBV) infection.
TG1050 has been developed as a targeted immunotherapy candidate indicated for the treatment of chronic hepatitis B, based on a viral vector expressing three HBV antigens.
Go deeper with GlobalData
Hepatitis B is a malignant liver infection caused by HBV infection, which can result in chronic infection and liver disease.
The condition can lead to death from cirrhosis of the liver and liver cancer if left untreated.
The Phase I/Ib trial is a first-in-man study conducted as an international, randomised, multi-centre, double-blind, placebo-controlled study.
It is intended to evaluate TG1050 in patients who are currently undergoing treatment for chronic HBV infection with standard-of-care anti-viral therapy.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe study is primarily focused on assessing the safety and tolerability of TG1050 while being administered in single and multiple doses, as well as determining the dose and schedule of the immunotherapy candidate for further development.
The secondary goals of the study are to determine the antiviral activity of and immune responses triggered by TG1050.
TG1050 has demonstrated its efficacy in inducing robust, broad and long-lasting HBV-specific T-cells, as well as exhibiting its anti-viral effects such as seroconversion to the surface antigen (HBsAg).
